Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host disease.

Martin PJ, Furlong T, Rowley SD, Pergam SA, Lloid M, Schubert MM, Horgan KJ, Storer BE.

Biol Blood Marrow Transplant. 2012 Jun;18(6):922-9. doi: 10.1016/j.bbmt.2011.11.010. Epub 2011 Nov 9.

2.

Skin-sparing mastectomy: a novel method to maximise training opportunities.

Vohra RS, McKenzie S, Turton EP, Horgan KJ, Achuthan R.

Surgeon. 2010 Oct;8(5):293-5. doi: 10.1016/j.surge.2010.05.005. Epub 2010 Jun 17. No abstract available.

PMID:
20709288
3.

6-benzyladenine metabolism during reinvigoration of mature Pinus radiata buds in vitro.

Zhang H, Horgan KJ, Reynolds PH, Jameson PE.

Tree Physiol. 2010 Apr;30(4):514-26. doi: 10.1093/treephys/tpp130. Epub 2010 Feb 8.

PMID:
20144924
4.

Solitary subcutaneous metastatic deposit from hepatocellular carcinoma.

Masannat YA, Achuthan R, Munot K, Merchant W, Meaney J, McMahon MJ, Horgan KJ.

N Z Med J. 2007 Nov 30;120(1266):U2837.

PMID:
18264206
5.

Ultrasound and MRI findings in appendicular and truncal fat necrosis.

Robinson P, Farrant JM, Bourke G, Merchant W, McKie S, Horgan KJ.

Skeletal Radiol. 2008 Mar;37(3):217-24. Epub 2007 Dec 4.

PMID:
18060546
6.

A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.

Gan TJ, Apfel CC, Kovac A, Philip BK, Singla N, Minkowitz H, Habib AS, Knighton J, Carides AD, Zhang H, Horgan KJ, Evans JK, Lawson FC; Aprepitant-PONV Study Group.

Anesth Analg. 2007 May;104(5):1082-9, tables of contents.

PMID:
17456656
7.

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.

Hesketh PJ, Grunberg SM, Herrstedt J, de Wit R, Gralla RJ, Carides AD, Taylor A, Evans JK, Horgan KJ.

Support Care Cancer. 2006 Apr;14(4):354-60. Epub 2006 Feb 1.

PMID:
16450086
8.

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.

Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Hustad CM, Horgan KJ, Skobieranda F; Aprepitant Moderately Emetogenic Chemotherapy Study Group.

Cancer. 2005 Oct 1;104(7):1548-55. Erratum in: Cancer. 2006 Apr 1;106(7):1641.

10.

The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.

Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit Rd, Carides AD, Taylor A, Evans JK, Horgan KJ.

Eur J Cancer. 2005 Jun;41(9):1278-85.

PMID:
15939263
11.

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.

Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F.

J Clin Oncol. 2005 Apr 20;23(12):2822-30. Erratum in: J Clin Oncol. 2005 Aug 20;23(24):5851. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
15837996
12.

Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.

Pendergrass K, Hargreaves R, Petty KJ, Carides AD, Evans JK, Horgan KJ.

Drugs Today (Barc). 2004 Oct;40(10):853-63. Review.

PMID:
15605119
14.

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.

de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ.

J Clin Oncol. 2003 Nov 15;21(22):4105-11. Epub 2003 Oct 14.

PMID:
14559891
15.

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group.

J Clin Oncol. 2003 Nov 15;21(22):4112-9. Epub 2003 Oct 14.

PMID:
14559886
16.

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group.

Cancer. 2003 Jun 15;97(12):3090-8.

17.

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ.

Eur J Cancer. 2003 May;39(8):1074-80.

PMID:
12736106
18.

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ.

Cancer. 2003 May 1;97(9):2290-300.

19.

Novel cytokinins: The predominant forms in mature buds of Pinus radiata.

Zhang H, Horgan KJ, Stewart Reynolds PH, Norris GE, Jameson PE.

Physiol Plant. 2001 May;112(1):127-134.

PMID:
11319024
20.

Distinct phenotype of leukemic T cells with various tissue tropisms.

Tanaka Y, Wake A, Horgan KJ, Murakami S, Aso M, Saito K, Oda S, Morimoto I, Uno H, Kikuchi H, Izumi Y, Eto S.

J Immunol. 1997 Apr 15;158(8):3822-9.

PMID:
9103449
21.

CD45RB expression defines two interconvertible subsets of human CD4+ T cells with memory function.

Horgan KJ, Tanaka Y, Luce GE, van Seventer GA, Nutman TB, Shaw S.

Eur J Immunol. 1994 May;24(5):1240-3.

PMID:
7910140
22.

Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with Hallmarks of gut-trophism.

Schweighoffer T, Tanaka Y, Tidswell M, Erle DJ, Horgan KJ, Luce GE, Lazarovits AI, Buck D, Shaw S.

J Immunol. 1993 Jul 15;151(2):717-29.

PMID:
7687621
23.

Differential expression of VLA-alpha 4 and VLA-beta 1 discriminates multiple subsets of CD4+CD45R0+ "memory" T cells.

Horgan KJ, Luce GE, Tanaka Y, Schweighoffer T, Shimizu Y, Sharrow SO, Shaw S.

J Immunol. 1992 Dec 15;149(12):4082-7.

PMID:
1360997
24.

CD31 expressed on distinctive T cell subsets is a preferential amplifier of beta 1 integrin-mediated adhesion.

Tanaka Y, Albelda SM, Horgan KJ, van Seventer GA, Shimizu Y, Newman W, Hallam J, Newman PJ, Buck CA, Shaw S.

J Exp Med. 1992 Jul 1;176(1):245-53.

25.

Crosslinking of the T cell-specific accessory molecules CD7 and CD28 modulates T cell adhesion.

Shimizu Y, van Seventer GA, Ennis E, Newman W, Horgan KJ, Shaw S.

J Exp Med. 1992 Feb 1;175(2):577-82.

26.

Postthymic differentiation of CD4 T lymphocytes: naive versus memory subsets and further specialization among memory cells.

Horgan KJ, Tanaka Y, Shaw S.

Chem Immunol. 1992;54:72-102. Review. No abstract available.

PMID:
1358112
27.

Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1.

van Seventer GA, Newman W, Shimizu Y, Nutman TB, Tanaka Y, Horgan KJ, Gopal TV, Ennis E, O'Sullivan D, Grey H, et al.

J Exp Med. 1991 Oct 1;174(4):901-13.

28.

Remote T cell co-stimulation via LFA-1/ICAM-1 and CD2/LFA-3: demonstration with immobilized ligand/mAb and implication in monocyte-mediated co-stimulation.

Van Seventer GA, Shimizu Y, Horgan KJ, Luce GE, Webb D, Shaw S.

Eur J Immunol. 1991 Jul;21(7):1711-8.

PMID:
1711977
29.

Four molecular pathways of T cell adhesion to endothelial cells: roles of LFA-1, VCAM-1, and ELAM-1 and changes in pathway hierarchy under different activation conditions.

Shimizu Y, Newman W, Gopal TV, Horgan KJ, Graber N, Beall LD, van Seventer GA, Shaw S.

J Cell Biol. 1991 Jun;113(5):1203-12.

30.

Activation-independent binding of human memory T cells to adhesion molecule ELAM-1.

Shimizu Y, Shaw S, Graber N, Gopal TV, Horgan KJ, Van Seventer GA, Newman W.

Nature. 1991 Feb 28;349(6312):799-802.

PMID:
1705667
31.

TCR V gene usage in autoimmunity.

Posnett DN, Horgan KJ, Friedman SM.

Immunol Ser. 1991;55:171-202. Review. No abstract available.

PMID:
1954285
32.
33.

The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells.

Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S.

J Immunol. 1990 Jun 15;144(12):4579-86.

PMID:
1972160
34.

Regulated expression and binding of three VLA (beta 1) integrin receptors on T cells.

Shimizu Y, Van Seventer GA, Horgan KJ, Shaw S.

Nature. 1990 May 17;345(6272):250-3.

PMID:
2139716
35.
37.

Acute renal failure due to mannitol intoxication.

Horgan KJ, Ottaviano YL, Watson AJ.

Am J Nephrol. 1989;9(2):106-9. Review.

PMID:
2500855

Supplemental Content

Loading ...
Support Center